Skip to main content

1 Result(s)

within Cyrine Ezzili Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients

    Dinaciclib is a novel selective inhibitor of cyclin-dependent kinase (CDK)1, CDK2, CDK5, and CDK9. We conducted a phase I study to investigate the effects of dinaciclib when administered with rituximab.

    Claire Fabre, Marco Gobbi, Cyrine Ezzili… in Cancer Chemotherapy and Pharmacology (2014)